69
Table 28. Cancer Therapies Known to Be Associated With
Cardiomyopathy
Class Agent(s)
Cardiac Function
Monitoring Often
Performed in Clinical
Practice
Pretherapy Serial
Anthracyclines Doxorubicin, epirubicin
X X
Alkylating agents Cyclophosphamide, ifosfamide,
melphalan
X
Antimicrotubule
agents
Docetaxel
Antimetabolites Fluorouracil, capecitabine,
fludarabine, decitabine
Anti-HER2 agents Trastuzumab, pertuzumab
X X
Monoclonal
antibodies
Rituximab
Tyrosine-kinase
inhibitors
Dabrafenib, dasatinib, lapatinib,
pazopanib, ponatinib, sorafenib,
trametinib, sunitinib, vandetanib,
imatinib, vandetanib
Immune
checkpoint
inhibitors
Nivolumab, ipilimumab,
pembrolizumab
Protease inhibitors Bortezomib, carfilzomib
Endocrine therapy Goserelin, leuprolide, flutamide,
bicalutamide, nilutamide
Chimeric antigen
receptor T-cell
therapy
Tisagenlecleucel,
axicabtageneciloleucel
X
Hematopoietic
stem cell
transplantation
Hematopoietic stem cell
transplantation
X
Radiation Chest
